Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

This Tech Stock Is 'Too Expensive,' Cramer Says: 'Wait For A Pullback'

Author: Avi Kapoor | December 08, 2023 10:07am

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Camtek Ltd. (NASDAQ:CAMT) is a "fabulous" company, but the stock is "too expensive." He recommended waiting for a pullback.

Cramer said he dislikes Novavax, Inc. (NASDAQ:NVAX) entirely. "I’ve done so for a very, very long time, even when it was much, much higher," he added.

When asked about Atkore Inc. (NYSE:ATKR), he said, "When I do anything involving steel, I immediately default to Nucor Corporation (NYSE:NUE). You have to do that, it’s the best in show."

Don’t forget to check out our premarket coverage here

The "Mad Money" host said he is worried about the fact that Coinbase Global, Inc. (NASDAQ:COIN) is "too expensive. Let it come in."

When asked about EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), he said, "The easy money has been made here. You got to find something else."

Cramer said American Eagle Outfitters, Inc. (NYSE:AEO) is good. "It did screw up in the past, though, I say Abercrombie & Fitch Co. (NYSE:ANF) is much better," he added.

Price Action:

  • Shares of Abercrombie & Fitch gained 1.1% to close at $77.94.
  • American Eagle rose 1.1% to $20.16 on Thursday.
  • EyePoint Pharmaceuticals gained 9.5% to $21.18.
  • Coinbase rose 1.2% to $136.19 during Thursday’s session.
  • Atkore shares gained 1.8%, while Nucor added 0.6%.
  • Novavax shares fell 0.9% to $5.53, while Camtek fell 0.7% to close at $62.15 on Thursday.

Now Read This: $1.7M Bet On Erasca? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

Posted In: AEO ANF ATKR CAMT COIN EYPT NUE NVAX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist